• Male or female aged 18 to 65 years (inclusive) at the time of informed consent.

• ADPKD diagnosis as confirmed by the presence of genetic mutations associated with ADPKD, including, but not limited to, the presence of PKD1 mutation. Note: Where genotyping is not included the medical history for a participant, genotyping may be completed at Pre-Screening.

• Class 1C, 1D, or 1E per Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD (Irazabal et al. 2015) (based upon prior magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan obtained \> 6 months prior to Screening, or MRI obtained during Pre-Screening).

• BMI ≥ 18.0 and ≤ 32.0 kg/m2 and weight ≥ 50 kg.

• Non-smoker and must not have used any tobacco or nicotine products within 2 months prior to Screening.

• Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 via the CKD EPI 2021 calculation (Inker et al. 2021).

⁃ 8\. Hematology and serum chemistry results at Screening that meet the following criteria:

• Platelets \> 150 × 10\^9/L

• Total white blood cell count \> 3.0 × 10\^9/L

• Absolute neutrophil count \> 1.5 × 10\^9/L

• Hemoglobin \> 110 g/L for females and \> 120 g/L for males

• Total and direct bilirubin \< 1.5 × ULN, unless elevated bilirubin is associated with a known benign condition (e.g., Gilbert's syndrome)

• Alanine aminotransferase (ALT) \< 1.5 × ULN

• Aspartate aminotransferase (AST) \< 1.5 × ULN

• Alkaline phosphatase (ALP) \< 1.5 × ULN

• Gamma-glutamyl transferase \< 2 × ULN Note: Screening laboratory testing may be repeated once at the discretion of the PI or designee to confirm out-of-range(exclusionary) results.